Navigation Links
Singulex Closes $19 Million Financing Round
Date:1/12/2009

ALAMEDA, Calif., Jan. 12 /PRNewswire/ -- Singulex, Inc. today announced that it has closed a $19 million financing round, led by JAFCO Co., Ltd. and supported by existing investors including OrbiMed Advisors and Fisk Ventures. The financing round will support the commercialization of Singulex technologies in the diagnostics market. As part of the financing, Hironori Hozoji, investment officer for JAFCO Life Science Investment, will join the company's Board of Directors.

"With these funds, we are confident we have the resources to develop our immunoassay technology for use in the diagnostics field," said Philippe Goix, PhD, CEO of Singulex. "Already, the assays we have developed and optimized for our pharmaceutical partners have enabled them to see biomarker level differences in blood samples with and without drugs that they had not been able to see before, thus offering new insights for their clinical trials."

Singulex has closed partnerships with multiple large pharmaceutical companies to use Erenna technology and immunoassays to help them better understand the effects of their compounds early in preclinical studies and clinical trials. With its ability to detect and measure minute protein biomarker changes at very low levels, Singulex's technology also has significant potential for clinical applications in personalized medicine across multiple diseases.

Singulex will use the funds from this financing to deploy its product and services in the emerging molecular clinical diagnostic market. Initially, the company will focus on cardiovascular disease risk diagnostics using its assay platform for the biomarker c Troponin I (cTnI), a well-validated marker for cardiac necrosis.

"Singulex's steady progress in publishing strong data from premier medical schools in the country indicated that the Erenna technology can make significant contributions to the diagnostics field, specifically in the cardiovascular area but also across a wide range of diseases. This makes an attractive investment opportunity," noted Hozoji. "Not only that, but the potential for the Singulex technology to be used to determine which patients respond to specific drugs should position the company to be a leader in personalized medicine."

About Singulex

Singulex develops and commercializes innovative product and service solutions that enable disease understanding and management for life science researchers and clinicians. Utilizing proprietary quantitative single molecule detection technology, Singulex provides unique biomarker answers that offer unprecedented level of sensitivity and accuracy of specific protein biomarker levels in a variety of biological samples. Singulex technology is currently used by academic and molecular diagnostic partners to further develop the significant clinical utility that the Erenna(TM) Immunoassay System enables. To learn more about Singulex, please visit us at http://www.singulex.com.

    Contact:
    Carolyn Hawley
    Porter Novelli Life Sciences for Singulex
    619-849-5375
    chawley@pnlifesciences.com


'/>"/>
SOURCE Singulex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Singulex Collaborates With Large Pharmaceutical Company in Erenna(TM) Technology Access Program
2. Karolinska Development Closes Fully Subscribed New Share Issue
3. Concentric Medical Closes on $15 Million Financing
4. Intradigm Closes Final Tranche of $21.4 Million Series B Financing
5. Diagnoplex Closes CHF10 Million ($8.3 Million) Series A Financing
6. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
7. MicroPhage Closes Latest Financing
8. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
9. CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate
10. Starfish Ventures Closes Australias Largest Venture Capital Fund With $185 Million Tech Fund
11. Valor Medical Closes $1.4 Million Convertible Debt and Receives ISO 13485 Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published ... how a patient who developed lymphedema after being treated for breast cancer benefitted from ... the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
Breaking Biology Technology:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
Breaking Biology News(10 mins):